Clinical trial
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
NCT00191854 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191854 |
|---|---|
| Title | Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line |
| Official title | Randomized Phase II Study of Biweekly Gemcitabine-Paclitaxel, Biweekly Gemcitabine-Carboplatin and Biweekly Gemcitabine-Cisplatin as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, paclitaxel, carboplatin, cisplatin |
| Enrollment | 147 |
| Start date | Mar 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Nov 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 2, 2010 |
| Countries | Brazil, China, India, Mexico, South Korea, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: